Evidence map›Paper›PMID 29236925›Full record

ArticleMemorias do Instituto Oswaldo Cruz2018

Increased thiol levels in antimony-resistant Leishmania infantum isolated from treatment-refractory visceral leishmaniasis in Brazil.

Lucas S Magalhães, Lays Gs Bomfim, Sthefanne G Mota, Geydson S Cruz, Cristiane B Corrêa, Diego M Tanajura, Michael W Lipscomb, Valéria M Borges, Amélia R de Jesus, Roque P de Almeida and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Memorias do Instituto Oswaldo Cruz, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Molecular Mechanisms of Drug Resistance inPathogens (Basel, Switzerland) · 2024
    Review
  3. GC-MS screening and antiparasitic action ofJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2021
    Article
  4. Article
  5. Frontiers in cellular and infection microbiology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Lucas S MagalhãesLaboratório de Biologia Molecular, Hospital Universitário, Universidade Federal de Sergipe, Aracaju, SE, Brasil.
Lays Gs BomfimLaboratório de Biologia Molecular, Hospital Universitário, Universidade Federal de Sergipe, Aracaju, SE, Brasil.
Sthefanne G MotaLaboratório de Biologia Molecular, Hospital Universitário, Universidade Federal de Sergipe, Aracaju, SE, Brasil.
Geydson S CruzLaboratório de Biologia Molecular, Hospital Universitário, Universidade Federal de Sergipe, Aracaju, SE, Brasil.
Cristiane B CorrêaLaboratório de Biologia Molecular, Hospital Universitário, Universidade Federal de Sergipe, Aracaju, SE, Brasil.
Diego M TanajuraLaboratório de Biologia Molecular, Hospital Universitário, Universidade Federal de Sergipe, Aracaju, SE, Brasil.
Michael W LipscombDepartment of Biology, Howard University, Washington DC, United States of America.
Valéria M BorgesInstituto Gonçalo Moniz, Fundação Oswaldo Cruz-Fiocruz, Salvador, BA, Brasil.
Amélia R de JesusLaboratório de Biologia Molecular, Hospital Universitário, Universidade Federal de Sergipe, Aracaju, SE, Brasil.
Roque P de AlmeidaLaboratório de Biologia Molecular, Hospital Universitário, Universidade Federal de Sergipe, Aracaju, SE, Brasil.
Tatiana R de MouraLaboratório de Biologia Molecular, Hospital Universitário, Universidade Federal de Sergipe, Aracaju, SE, Brasil.
Universidade Federal de Sergipe · BRFundação Oswaldo Cruz · BRHoward University · US

Funding

Crosstalk and the cytoskeleton in dendritic cell antigen presentationSC2GM103741 · NIGMS · HOWARD UNIVERSITY · PI LIPSCOMB, MICHAEL W · 2015 to 2017
$441k
NIGMS NIH HHS SC2 GM103741
6 · The paper itself

Abstract

BACKGROUND Treatment-refractory visceral leishmaniasis (VL) has become an important problem in many countries. OBJECTIVES We evaluated the antimony-resistance mechanisms of Leishmania infantum isolated from VL patients refractory or responsive to treatment with pentavalent antimony. METHODS Strains isolated from antimony-refractory patients (in vitro antimony-resistant isolates) and antimony-responsive patients (in vitro antimony-sensitive isolates) were examined. Morphological changes were evaluated by transmission electron microscopy after trivalent antimony exposure. P-glycoprotein (P-gp) efflux pump activity was evaluated using the pump-specific inhibitor verapamil hydrochloride, and the role of thiol in trivalent antimony resistance was investigated using the enzymatic inhibitor L-buthionine sulfoximine. FINDINGS Antimony treatment induced fewer alterations in the cellular structure of L. infantum resistant isolates than in that of sensitive isolates. P-gp efflux activity was not involved in antimony resistance in these isolates. Importantly, the resistant isolates contained higher levels of thiol compared to the sensitive isolates, and inhibition of thiol synthesis in the resistant isolates recovered their sensitivity to trivalent antimony treatment, and enhanced the production of reactive oxygen species in promastigotes exposed to the drug. MAIN CONCLUSIONS Our results demonstrate that isolates from patients with antimony-refractory VL exhibited higher thiol levels than antimony-sensitive isolates. This indicates that redox metabolism plays an important role in the antimony-resistance of New World VL isolates.

Indexed as

AntimonyButhionine SulfoximineDrug ResistanceEnzyme InhibitorsHumansLeishmania infantumLeishmaniasis, VisceralMicroscopy, Electron, TransmissionParasitic Sensitivity TestsSulfhydryl CompoundsAntimonyButhionine SulfoximineEnzyme InhibitorsSulfhydryl Compounds

Identifiers

PMID29236925
PMCPMC5722267
OpenAlexW2775260163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.